TY - JOUR
T1 - Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease
AU - De Souza, Errol B.
AU - Whitehouse, Peter J.
AU - Kuhar, Michael J.
AU - Price, Donald L.
AU - Vale, Wylie W.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1986
Y1 - 1986
N2 - Alzheimer's disease is a progressive degenerative disease of the nervous system characterized neuropathologically by the presence of senile plaques and neurofibrillary tangles in amygdala, hippocampus and neocortex1-4. Dysfunction and death of basal forebrain cholinergic neurones projecting to forebrain targets5,6 are associated with marked decreases in cholinergic markers, including the activity of choline acetyltransferase (ChAT)2,3,7-9. Although cortical levels of somatostatin 10-12 and somatostatin receptors13 are reduced in Alzheimer's, no consistent changes have been reported in other neuropeptide systems12,14-17. We have now examined in control and Alzheimer's brain tissues pre- and postsynaptic markers of corticotropin-releasing factor (CRF), a hypothalamic peptide regulating pituitary-adrenocortical secretion 18,19 which also seems to act as a neu retransmitter in the central nervous system (CNS) (reviewed in refs 20, 21). We have found that in Alzheimer's, the concentrations of CRF-like immunoreactivity (CRF-IR) are reduced and that there are reciprocal increases in CRF receptor binding in affected cortical areas. These changes are significantly correlated with decrements in ChAT activity. Our results strongly support a neurotransmitter role for CRF in brain and demonstrate, for the first time, a modulation of CNS CRF receptors associated with altered CRF content. These observations further suggest a possible role for CRF in the pathophysiology of the dementia. Future therapies directed at increasing CRF levels in brain may prove useful for treatment.
AB - Alzheimer's disease is a progressive degenerative disease of the nervous system characterized neuropathologically by the presence of senile plaques and neurofibrillary tangles in amygdala, hippocampus and neocortex1-4. Dysfunction and death of basal forebrain cholinergic neurones projecting to forebrain targets5,6 are associated with marked decreases in cholinergic markers, including the activity of choline acetyltransferase (ChAT)2,3,7-9. Although cortical levels of somatostatin 10-12 and somatostatin receptors13 are reduced in Alzheimer's, no consistent changes have been reported in other neuropeptide systems12,14-17. We have now examined in control and Alzheimer's brain tissues pre- and postsynaptic markers of corticotropin-releasing factor (CRF), a hypothalamic peptide regulating pituitary-adrenocortical secretion 18,19 which also seems to act as a neu retransmitter in the central nervous system (CNS) (reviewed in refs 20, 21). We have found that in Alzheimer's, the concentrations of CRF-like immunoreactivity (CRF-IR) are reduced and that there are reciprocal increases in CRF receptor binding in affected cortical areas. These changes are significantly correlated with decrements in ChAT activity. Our results strongly support a neurotransmitter role for CRF in brain and demonstrate, for the first time, a modulation of CNS CRF receptors associated with altered CRF content. These observations further suggest a possible role for CRF in the pathophysiology of the dementia. Future therapies directed at increasing CRF levels in brain may prove useful for treatment.
UR - http://www.scopus.com/inward/record.url?scp=0022573696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022573696&partnerID=8YFLogxK
U2 - 10.1038/319593a0
DO - 10.1038/319593a0
M3 - Article
C2 - 3003585
AN - SCOPUS:0022573696
SN - 0028-0836
VL - 319
SP - 593
EP - 595
JO - Nature
JF - Nature
IS - 6054
ER -